Tendinitis and Bursitis: Pathophysiology, Pharmacologic Management, and Clinical Pearls

Every day, clinicians encounter patients who report pain, swelling, and functional limitation in the shoulder, elbow, knee, or ankle. In 2023, the American College of Rheumatology reported that tendinitis and bursitis account for approximately 12% of all outpatient musculoskeletal visits, underscoring the clinical burden of these common overuse injuries. A typical scenario involves a 45‑year‑old office worker who develops a painful, erythematous swelling over the lateral elbow after repetitive mouse use—classic lateral epicondylitis (tennis elbow). Prompt recognition and evidence‑based pharmacologic intervention can prevent chronic pain, reduce healthcare costs, and improve quality of life.

Introduction and Background

Tendinitis and bursitis, collectively known as overuse inflammatory disorders of the musculoskeletal system, have been described since antiquity. The term “tendinitis” was first coined in the 19th century to differentiate inflammatory tendon disease from the earlier concept of “tendonitis” as a nonspecific injury. Epidemiologic studies now show that tendinitis affects 1–2% of the general population annually, with incidence peaking in the 30‑to‑60‑year age range and higher in manual laborers, athletes, and individuals with repetitive overhead activities.

At the cellular level, tendinitis is characterized by collagen fiber disruption, neovascularization, and an influx of inflammatory mediators such as prostaglandin E2 (PGE2), tumor necrosis factor‑α (TNF‑α), and interleukin‑1β (IL‑1β). Bursitis, on the other hand, involves inflammation of the synovial‑lined fluid‑filled bursa, often secondary to mechanical irritation, infection, or systemic inflammatory disease. Both conditions share a common pathophysiologic pathway: mechanical overload leads to microtrauma, which triggers an inflammatory cascade that perpetuates pain and limits function.

Pharmacologic management typically targets the inflammatory mediators and pain pathways. Non‑steroidal anti‑inflammatory drugs (NSAIDs), including selective cyclo‑oxygenase‑2 (COX‑2) inhibitors and non‑selective NSAIDs, remain first‑line agents. Corticosteroid injections provide potent anti‑inflammatory effects but carry risks of tendon rupture and local tissue atrophy. Emerging biologic therapies, such as platelet‑rich plasma (PRP) and autologous conditioned serum, aim to modulate the healing environment, though robust evidence is still evolving.

Mechanism of Action

NSAIDs: Cyclo‑oxygenase Inhibition

NSAIDs exert their anti‑inflammatory effects by competitively inhibiting cyclo‑oxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins from arachidonic acid. Non‑selective NSAIDs block both COX‑1 and COX‑2, diminishing prostaglandin‑mediated vasodilation, increased vascular permeability, and nociceptor sensitization. Selective COX‑2 inhibitors, such as celecoxib, preferentially inhibit the inducible COX‑2 isoform, sparing COX‑1‑mediated gastric prostaglandin production and thereby reducing gastrointestinal toxicity.

Corticosteroids: Glucocorticoid Receptor Modulation

Glucocorticoids bind to cytosolic glucocorticoid receptors (GRs), forming a ligand‑receptor complex that translocates to the nucleus. This complex interacts with glucocorticoid response elements (GREs) to up‑regulate anti‑inflammatory genes (e.g., annexin‑1, lipocortin) and down‑regulate pro‑inflammatory cytokines (e.g., TNF‑α, IL‑1β). The result is a rapid suppression of leukocyte infiltration, cytokine production, and fibroblast proliferation, which translates clinically to decreased edema and pain within hours of injection.

Biologic Therapies: Platelet‑Rich Plasma and Growth Factors

PRP is an autologous concentration of platelets (>3–5× baseline) suspended in a small volume of plasma. Upon activation, platelets release growth factors—including platelet‑derived growth factor (PDGF), transforming growth factor‑β (TGF‑β), vascular endothelial growth factor (VEGF), and insulin‑like growth factor‑1 (IGF‑1)—that modulate cell proliferation, angiogenesis, and extracellular matrix remodeling. The hypothesis is that PRP shifts the tendon microenvironment from a catabolic to an anabolic state, thereby accelerating tissue repair and reducing pain.

Clinical Pharmacology

Pharmacokinetic and pharmacodynamic profiles of NSAIDs and corticosteroids vary considerably, influencing efficacy, safety, and dosing strategies.

Pharmacodynamics: The analgesic effect of NSAIDs correlates with plasma concentration and COX inhibition. For example, ibuprofen achieves 80–90 % COX‑1 inhibition at 400 mg and 70–80 % COX‑2 inhibition at 600 mg. The therapeutic window for systemic NSAIDs is narrow; doses above 800 mg/day for ibuprofen or 1500 mg/day for naproxen increase GI and renal adverse events without proportional benefit. Corticosteroid injections provide a high local concentration (>10 mg/mL) of prednisolone or methylprednisolone, achieving >90 % suppression of pro‑inflammatory cytokines within 24 h. The duration of analgesia depends on the depot formulation; triamcinolone acetonide has a prolonged effect (up to 8 weeks) due to its slow release.

Therapeutic Applications

FDA‑approved indications for NSAIDs include osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute musculoskeletal pain. For tendinitis and bursitis, the evidence supports short‑course oral NSAIDs (7–14 days) and single‑dose intra‑articular corticosteroid injections. Off‑label uses include PRP injections and autologous conditioned serum for chronic tendinopathies, though high‑quality randomized trials are limited.

• Ibuprofen – 200–400 mg PO every 6–8 h, max 1200 mg/day for acute pain; 400–600 mg PO every 8 h for chronic tendinopathy, max 2400 mg/day.

• Naproxen – 250 mg PO BID for acute pain; 500 mg PO BID for chronic tendinopathy.

• Diclofenac – 50 mg PO BID or topical gel 1 % twice daily for acute pain.

• Celecoxib – 200 mg PO daily for chronic tendinopathy; 400 mg PO daily for high‑risk gastrointestinal patients.

• Corticosteroid Injection – 1 mL of 40 mg/mL methylprednisolone acetate or 10 mg/mL triamcinolone acetonide per injection; repeat only after 6–8 weeks.

1. Pediatric – NSAIDs are generally safe in children >6 months; dosing based on weight (e.g., ibuprofen 5–10 mg/kg PO every 6–8 h).

2. Geriatric – Reduced renal clearance necessitates lower NSAID doses (e.g., ibuprofen 200 mg PO BID). Caution with concurrent antihypertensives.

3. Renal Impairment – NSAIDs contraindicated in stage 4–5 CKD; use acetaminophen or consider topical NSAIDs.

4. Hepatic Impairment – Avoid NSAIDs with high hepatic metabolism; use ibuprofen or acetaminophen cautiously.

5. Pregnancy – NSAIDs contraindicated in the third trimester; consider acetaminophen or low‑dose ibuprofen in the second trimester if necessary.

Adverse Effects and Safety

Common side effects of NSAIDs include dyspepsia (10–20%), abdominal pain (5–10%), and dizziness (3–5%). Serious adverse events—upper GI bleeding (~1–5 % in high‑dose users), nephrotoxicity (1–3 % in elderly or volume‑depleted patients), and cardiovascular events (0.5–1 % in high‑risk patients)—are dose‑dependent and cumulative. Corticosteroid injections carry a risk of tendon rupture (0.02–0.1 % per injection), localized infection (0.1–0.3 %), and transient hyperglycemia (up to 10 % in diabetics).

Monitoring parameters: baseline renal function (serum creatinine, eGFR), liver enzymes (AST/ALT), and blood pressure. For patients on chronic NSAIDs, periodic stool guaiac testing and proton‑pump inhibitor (PPI) prophylaxis may be warranted. Contraindications include active peptic ulcer disease, severe renal insufficiency (eGFR < 30 mL/min/1.73 m²), uncontrolled hypertension, and history of hypersensitivity to the drug.

Clinical Pearls for Practice

• “Rule of 7” – If a patient reports pain for >7 days, consider imaging or referral; chronic tendinopathy rarely resolves with NSAIDs alone.

• Topical vs Oral – Topical diclofenac 1 % gel delivers 1–2 % systemic exposure and is preferable for patients with GI risk.

• Injection Timing – Schedule corticosteroid injections during the low‑activity period (e.g., early morning) to maximize analgesic benefit and reduce systemic absorption.

• PRP “Gold Standard” – PRP is most effective when the platelet concentration is 5–10× baseline; avoid excessive leukocyte contamination.

• “No NSAID, No Pain” – For patients on anticoagulants, use acetaminophen or a short course of NSAID with PPI prophylaxis to mitigate bleeding risk.

• Dosage “Rule of 3” – For ibuprofen, limit total daily dose to ≤1200 mg unless under close supervision; higher doses increase GI risk without added benefit.

• Re‑evaluation “After 2 Weeks” – Reassess pain and function after 2 weeks of NSAIDs; if no improvement, consider corticosteroid injection or physiotherapy referral.

Comparison Table

Exam‑Focused Review

Common question stems: “A 52‑year‑old man presents with lateral elbow pain after repetitive overhead activity. Which pharmacologic agent is best for acute relief?” or “Which drug class is contraindicated in a patient with a history of peptic ulcer disease?” Students often confuse the COX‑selectivity of NSAIDs with their cardiovascular risk profile. Key differentiators include:

• COX‑1 inhibition → GI toxicity; COX‑2 inhibition → reduced GI but increased cardiovascular events.

• NSAID half‑life: naproxen > ibuprofen; longer half‑life allows BID dosing.

• Corticosteroid injection vs oral NSAIDs: injection provides rapid, high‑local concentration but risks tendon rupture; oral NSAIDs provide systemic anti‑inflammatory effect with GI risk.

• PRP vs corticosteroid: PRP is regenerative, not anti‑inflammatory; evidence is still emerging.

Must‑know facts for NAPLEX/USMLE:

1. NSAIDs inhibit cyclo‑oxygenase, reducing prostaglandin synthesis.

2. Selective COX‑2 inhibitors (celecoxib) spare gastric mucosa but increase cardiovascular risk.

3. Corticosteroid injections are effective but risk tendon rupture; limit to 1–2 per year.

4. PRP is autologous; efficacy depends on platelet concentration.

5. Patients on anticoagulants should avoid NSAIDs unless on PPI prophylaxis.

Key Takeaways

1. Overuse injuries such as tendinitis and bursitis affect ~12 % of outpatient musculoskeletal visits.

2. Inflammatory mediators (PGE2, TNF‑α, IL‑1β) drive pain and tissue damage.

3. NSAIDs reduce prostaglandin synthesis; COX‑2 selectivity lowers GI risk but raises cardiovascular risk.

4. Corticosteroid injections provide rapid, potent anti‑inflammatory effect but risk tendon rupture and local infection.

5. PRP offers a regenerative approach; optimal platelet concentration is 5–10× baseline.

6. Use the lowest effective NSAID dose for the shortest duration to minimize GI and renal adverse events.

7. Topical NSAIDs are preferable for patients with GI risk.

8. Monitor renal function, liver enzymes, and blood pressure in patients on chronic NSAIDs.

9. Avoid NSAIDs in patients with active peptic ulcer disease, severe renal impairment, or uncontrolled hypertension.

10. Reassess pain after 2 weeks of NSAIDs; consider corticosteroid injection or physiotherapy if inadequate response.

Remember: A tailored, evidence‑based approach to tendinitis and bursitis not only alleviates pain but also preserves tendon integrity and prevents chronic disability.